Zhejiang Huahai Pharmaceutical Co. Ltd.

Form 483 issued June 28, 2019 · Linhai, China

Inspection
Jun 24 – Jun 28, 2019
Observations
5
Pages
4
FEI number
3003999190

In short: On June 28, 2019, FDA issued a Form 483 with 5 observations to Zhejiang Huahai Pharmaceutical Co. Ltd. in Linhai, Zhejiang (FEI 3003999190) after an inspection that ran Jun 24 – Jun 28, 2019. The investigator was Jonathan W. Chapman. Most observations concern production and quality system.

At a glance

Production and quality system account for 3 of 5 observations.

Production2
Quality system1
Laboratory controls1
Other1

What FDA observed

Preview: the opening words of each observation

Dashed: section inferred by FDA Intel and checked against the regulation text

  1. 01

    There is a failure to thoroughly review…

  2. 02

    Procedures designed to prevent…

  3. 03

    Changes to written procedures are not…

  4. 04

    control and…

1 more observation

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Zhejiang Huahai Pharmaceutical Co. Ltd.?

FDA listed 5 observations on this Form 483, mostly about production, quality system and laboratory controls. The opening words of each observation are shown on this page.

Who inspected Zhejiang Huahai Pharmaceutical Co. Ltd.?

Jonathan W. Chapman is named on this Form 483, for the inspection of Jun 24 – Jun 28, 2019. Each investigator has a profile showing what they cite most.

When was Zhejiang Huahai Pharmaceutical Co. Ltd. inspected by FDA?

The inspection ran Jun 24 – Jun 28, 2019, and the Form 483 is dated June 28, 2019.

How do I get the full Form 483 for Zhejiang Huahai Pharmaceutical Co. Ltd.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free